Patents Assigned to Cytokinetics, Inc.
  • Bisamide sarcomere activating compounds and uses thereof
    Patent number: 10899746
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: January 26, 2021
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Cardiac sarcomere inhibitors
    Patent number: 10836755
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: November 17, 2020
    Assignee: CYTOKINETICS, INC.
    Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Wenyue Wang, Luke W. Ashcraft
  • Amino-pyrimidine skeletal muscle modulators
    Patent number: 10765624
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 8, 2020
    Assignee: CYTOKINETICS, INC.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Bisamide sarcomere activating compounds and uses therof
    Patent number: 10723720
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 28, 2020
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Compounds, compositions and methods
    Patent number: 10385023
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: August 20, 2019
    Assignee: CYTOKINETICS, INC.
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.
  • Combination ALS therapy
    Patent number: 10272082
    Abstract: Provided is a method for treating ALS in a subject, comprising administering to the subject a therapeutically effective amount of riluzole and a therapeutically effective amount of CK-2017357. Also provided are methods of reducing the variability of riluzole exposure (e.g., Cmax and/or AUC24h) in a subject, methods of reducing the variability of riluzole exposure (e.g., Cmax and/or AUC24h) between two or more subjects, methods of decreasing the total daily dose of riluzole in a subject, methods of increasing the half-life of riluzole in a subject, methods for decreasing the frequency of riluzole dosing in the subject, and methods for reducing the incidence and/or severity of adverse events in a subject treated with riluzole.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: April 30, 2019
    Assignee: Cytokinetics, Inc.
    Inventors: Jesse Cedarbaum, John Mao, Fady Malik, Andrew A. Wolff
  • Amino-pyrimidine skeletal muscle modulators
    Patent number: 10272030
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: April 30, 2019
    Assignee: Cytokinetics, Inc.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
    Patent number: 10100043
    Abstract: Provided are cycloalkyl- and cycloalkenyl-substituted benzaldehydes and heteroaldehydes of formula (I) that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions containing the modulators, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 16, 2018
    Assignees: Global Blood Therapeutics, Inc., Cytokinetics, Inc.
    Inventors: Brian Metcalf, Chihyuan Chuang, Zhe Li
  • Substituted pyridazines as skeletal muscle modulators
    Patent number: 10076519
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: September 18, 2018
    Assignee: CYTOKINETICS, INC.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Scott Collibee, Chihyuan Chuang, Jeff Gardina, Bradley P. Morgan, Alex R. Muci, Xiangping Qian, Jeffrey Warrington, Zhe Yang, Pu-Ping Lu, Antonio Romero
  • Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
    Patent number: 9994528
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R2, R4, R5, R6, R7, R8, R9, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: June 12, 2018
    Assignee: Cytokinetics, Inc.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Scott Collibee, Chihyuan Chuang, Jeff Gardina, Bradley P. Morgan, Alex R Muci, Xiangping Qian, Antonio Romero, Jeffrey Warrington, Zhe Yang
  • Amino-pyrimidine skeletal muscle modulators
    Patent number: 9730886
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: August 15, 2017
    Assignee: Cytokinetics, Inc.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Substituted pyridazines as skeletal muscle modulators
    Patent number: 9604965
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: March 28, 2017
    Assignee: Cytokinetics, Inc.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Scott Collibee, Chihyuan Chuang, Jeff Gardina, Bradley P. Morgan, Alex R. Muci, Xiangping Qian, Jeffrey Warrington, Zhe Yang, Pu-Ping Lu, Antonio Romero
  • Certain heterocycles, compositions thereof, and methods for their use
    Patent number: 9278962
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: March 8, 2016
    Assignee: Cytokinetics, Inc.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Chihyuan Chuang, Scott Collibee, Pu-Ping Lu, Bradley Morgan, Alex Muci, Xiangping Qian, Jeffrey Warrington, Zhe Yang
  • SUBSTITUTED ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
    Publication number: 20160039801
    Abstract: Provided are cycloalkyl- and cycloalkenyl-substituted benzaldehydes and heteroaldehydes of formula (I) that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions containing the modulators, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Applicants: CYTOKINETICS, INC., GLOBAL BLOOD THERAPEUTICS, INC.
    Inventors: Brian METCALF, Chihyuan CHUANG, Zhe LI
  • SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT
    Publication number: 20160016906
    Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 21, 2016
    Applicants: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Sheng Cui, Henry Morrison, Karthik Nagapudi, Shawn Walker, Charles Bernard, Karl Bennett Hansen, Neil Fred Langille, Alan Martin Allgeier, Steven Mennen, Jacqueline Woo, Bradley Paul Morgan, Alex Muci
  • Compounds, compositions and methods
    Patent number: 9150564
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: October 6, 2015
    Assignee: CYTOKINETICS, INC.
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.
  • Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
    Patent number: 9133123
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R2, R4, R5, R6, R7, R8, R9, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: September 15, 2015
    Assignee: Cytokinetics, Inc.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Scott Collibee, Chihyuan Chuang, Jeff Gardina, Bradley P. Morgan, Alex R. Muci, Xiangping Qian, Antonio Romero, Jeffrey Warrington, Zhe Yang
  • Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
    Patent number: 9018210
    Abstract: Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: April 28, 2015
    Assignees: Global Blood Therapeutics, Inc., Cytokinetics, Inc., The Regents of the University of California
    Inventors: Brian Metcalf, Chihyuan Chuang
  • Certain amino-pyrimidines, compositions thereof, and methods for their use
    Patent number: 9018223
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 28, 2015
    Assignee: Cytokinetics, Inc.
    Inventors: Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang
  • Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
    Patent number: 9012450
    Abstract: Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: April 21, 2015
    Assignees: Global Blood Therapeutics, Inc., Cytokinetics, Inc., The Regents of the University of California
    Inventors: Brian Metcalf, Chihyuan Chuang, Jeffrey Warrington, Kumar Paulvannan, Matthew P. Jacobson, Lan Hua, Bradley Morgan